Aim: Hypogonadotropic hypogonadism (HH) is a condition caused by the deficient secretion of pituitary gonadotropins, leading to diminished ovarian function. Several studies of in vitro fertilization (IVF) in women with HH revealed acceptable clinical pregnancy outcomes but high multiple pregnancy rates after multiple fresh embryo transfer (ET). The purpose of this study was to analyze the outcomes of combined freeze-all embryos and single vitrified-warmed ET in women with HH. Methods: Of 91 infertile women with HH (basal luteinizing hormone and follicle-stimulating hormone levels <2.0 mIU/mL), we excluded patients aged ≥40 years (n = 2) and women who preferred fresh ET (n = 10). Seventy-nine women underwent 117 oocyte retrieval cycles and 135 vitrified-warmed ET during hormone replacement (HR) cycles from 2008 to 2014 at the Kato Ladies Clinic and Juntendo University Hospital. Results: In 26 single cleavage ET cycles, the rates of clinical pregnancy and live birth were 34.6% (9/26 ET) and 26.9% (7/26 ET), respectively. Regarding the outcomes after single vitrified-warmed blastocyst transfer, clinical pregnancy and live birth rates were 65.1% (71/109 ET) and 50.5% (55/109 ET), respectively. Multiple conceptions and ovarian hyperstimulation syndrome did not occur in any of the women with HH. Conclusion: Our results demonstrated that IVF followed by single vitrified-warmed ET in adjusted endocrine milieu during the HR cycle is an effective fertility treatment for women with HH and decreases the incidence of complications, including multiple conceptions.
Introduction
Decreased synthesis or secretion of pituitary gonadotropins results in impaired gonadal function, which is a condition known as hypogonadotropic hypogonadism (HH). [1] [2] [3] HH is caused by deficiencies in hypothalamic endogenous gonadotropin-releasing hormone (GnRH) release or pituitary gonadotropin secretion, leading to an imbalance in the hypothalamic-pituitary-gonadal (HPG) axis and diminished ovarian function. Therefore, women with HH show symptoms of hypoestrogenism, ovulation disorders and amenorrhea. However, according to the data of an ovarian function biomarker, anti-Müllerian hormone, most women with HH have age-dependent ovarian reserve. 4 Therefore, optimal induction of gonadotropin secretion by pulsatile GnRH or continuous gonadotropin administration may improve folliculogenesis and ovulation, leading to improving pregnancy rates theoretically. [5] [6] [7] Pulsatile GnRH therapy can be used to recover the periodic gonadotropin secretion; however, some patients suffer from the use of the portable pump for injection of GnRH for several weeks, and it is ineffective therapy for primary pituitary failure. 8 In general, to promote follicular growth and maturation, exogenous gonadotropins, such as human menopausal gonadotropin (hMG) or a combination of recombinant luteinizing hormone (LH) and follicle-stimulating (FSH), are administered followed by an injection of human chorionic gonadotropin (hCG). [9] [10] [11] The conventional ovulation induction procedure for patients with HH is daily low-dose injections of gonadotropins with the aim of producing a few follicles without complications, such as multiple conceptions and ovarian hyperstimulation syndrome (OHSS). 8, 11 However, mild ovarian stimulation often fails to induce follicle development because the parameters necessary to predict the threshold for ovarian response are not available in patients with HH. Therefore, it is difficult to find an individual optimal ovarian stimulation with daily gonadotropin injection in infertile women with HH.
Assisted reproductive technology, including in vitro fertilization (IVF), has developed in recent years. In particular, the advantages of vitrification methods have allowed a high survival rate of embryos after warming, in addition to pregnancy outcomes comparable to those of fresh embryos. 12 Several studies have reported the pregnancy outcomes after IVF in women with HH. 9, 13, 14 However, in these studies, multiple fresh embryo transfer (ET) was mainly performed in the oocyte retrieval cycles. These studies demonstrated that multiple fresh ET in patients with HH produced acceptable clinical pregnancy outcomes with a high multiple pregnancy rate. 13, 14 The freezeall policy followed by single frozen-warmed ET has increasingly been used as the IVF treatment strategy with low incidence of complications, including multiple conceptions and OHSS. This strategy can avoid the need for ET under nonphysiological conditions. 12, 15, 16 Furthermore, this strategy allows for ET to be performed later in a cycle along with hormone replacement (HR), which addresses luteal hypofunction in women with HH. Therefore, we hypothesized that combined treatment with freeze-all embryos and single vitrified-warmed ET during the HR cycle may be physiological and beneficial as an IVF strategy for women with HH, yet the reports on the pregnancy 
Methods

Patients
This study was approved by the institutional review boards of Kato Ladies Clinic (approval number: and Juntendo University Hospital (approval number: 16-086). Ninety-one consecutive infertile women with HH underwent oocyte retrieval from January 2008 to December 2014 at Kato Ladies Clinic and Juntendo University Hospital. The diagnosis of HH was based on primary or secondary amenorrhea with extremely low basal gonadotropin levels: basal LH and FSH levels <2.0 mIU/mL. We planned oocyte retrieval after ovarian stimulation, cryopreservation of all embryos and single vitrified-warmed ET during the HR cycle. We excluded patients aged ≥40 years (n = 2) and women who preferred fresh ET (n = 10) and recruited 117 oocyte retrieval cycles and 137 ET cycles in 79 patients (Fig. 1) . The follow-up data of the pregnancy outcomes of all patients were available. No woman had conceived previously or had experienced a serious medical disorder. Written informed Figure 1 Flow diagram of patients included in the study. Of 91 consecutive infertile women with hypogonadotropic hypogonadism, we excluded patients aged ≥40 years (n = 2) and women who preferred fresh embryo transfer (ET) (n = 10) and recruited 117 oocyte retrieval cycles in 79 patients. In two cycles, no competent embryo for freezing was obtained after oocyte retrieval and IVF, and we classified 137 ET cycles 77 patients into 26 cleavage ET cycles and 111 blastocyst transfer cycles.
consent was obtained from all women undergoing IVF treatment at the centers after they were informed that their deidentified data could be used for a retrospective study.
Controlled ovarian stimulation
All women were monitored using ultrasonography and serum hormone levels at day 3 of menstruation and received 75-300 IU of hMG (Ferring Pharmaceuticals, Saint Prex, Switzerland, or Kowa Pharmaceuticals, Aichi, Japan) daily. In all cycles, we confirmed developed follicles and administered 5000 IU of hCG (Mochida Pharmaceutical, Tokyo, Japan, or ASKA Pharmaceutical, Tokyo, Japan) by intramuscular injection. The initial dose use of hMG was 150-225 IU daily and was adjusted based on the individual patient's ovarian response. Oocyte retrieval was usually performed tranvaginally 32-35 h after hCG injection.
Insemination and embryo culture
Conventional IVF or intracytoplasmic sperm injection (ICSI) was performed approximately 3 or 5 h after oocyte retrieval, respectively. 17 HTF medium (Kitazato corporation, Shizuoka, Japan) supplemented with 10% serum substitute supplement (Irvine Scientific, CA, USA) was used as the fertilization medium. Fertilization assessment was performed 16-20 h after conventional IVF or ICSI (day 1). Typically, fertilized zygotes were cultured individually in 20 μL of Quinn Advantage Protein Plus cleavage medium (Origio, Målov, Denmark) on days 1-3. Following this, most of embryos were transferred to Quinn Advantage Protein Plus blastocyst medium (Origio) on days 4-6. All embryos were cultured at 37 C under 5% O 2 , 5% CO 2 and 90% N 2 with 100% humidity in water jacket incubators or nonhumidified incubators (Astec Co. Ltd., Fukuoka, Japan).
Vitrification and ET
All embryos were cultured to the cleavage embryo or blastocyst stages. We excluded the cleavage embryos of Veeck classification Grade 5, two to three cell embryos at 2 days and two to four cell embryos at 3 days after fertilization, and the blastocysts of Gardner classification Grade 1-3 at 7 days after fertilization. Selected morphologically and developmentally competent embryos were vitrified for subsequent use in ET cycles. The Cryotop ® method of vitrification (Kitazato Corporation, Shizuoka, Japan) was used, as described previously. 17, 18 In the HR cycle, the administration of estradiol (Hisamitsu Pharmaceutical Co., Inc., Tokyo, Japan, or Bayer AG., Leverkusen, Germany) was started from day 2 or 3 of the cycle. Dydrogesterone (30 mg/day, Daiichi Sankyo Company, Limited, Tokyo, Japan) was added from day 11 of the cycle; blastocysts were transferred 5-7 days later. Dydrogesterone was routinely administered orally during the early luteal phase after the vitrifiedwarmed ET procedures. In addition, intramuscular (ASKA Pharmaceutical. Co., Ltd.) or intravaginal progesterone (Ferring Pharmaceuticals) was administered until the 8th to 9th week of pregnancy.
Data analysis
All analyses were conducted using JMP (SAS, NC, USA). The cumulative live birth rates were calculated by two approaches. The first method is referred to as 'crude live birth rate', which calculates the outcome by dividing the number of women achieving live birth after a predetermined number of cycles by the total number of women who were scheduled for oocyte retrieval. The second method is referred to as 'expected live birth rate', which estimates the cumulative live birth rate by taking into account the effect of censoring (Kaplan-Meier method).
Results
Baseline patient characteristics
The demographic characteristics of the 79 women with HH are shown in Table 1 . The frequency of causes of HH included the following rates: 5.1% for pituitary tumor or surgery for pituitary tumor, 39.2% for reduction of body weight and 55.7% for unexplained. The average patient age and body mass index were 32.6 AE 0.5 years and 18.0 AE 0.3 kg/m 2 , respectively. The basal serum levels of estradiol FSH,and and LH prolactin were 22.5 AE 2.3 pg./mL, 0.3 AE 0.1 mIU/mL, 0.2 AE 0.0 mIU/mL, and 6.6 AE 9.9 pg./mL, respectively.
IVF outcomes
The outcomes of 117 IVF/ICSI cycles in 79 women are shown in Table 2 . The mean duration of ovarian stimulation was 12.2 AE 0.3 days, and the total amount of gonadotropin injected and the serum level of estradiol on the day of hCG injection were 2292 AE 96 IU and 1817 AE 113 pg./mL, respectively.
The mean numbers of retrieved oocytes, fertilized oocytes and cleaved embryos per oocyte retrieval cycle were 9.9 AE 0.7, 7.0 AE 0.5 and 6.3 AE 0.5, respectively. Fertilization rates after conventional IVF and ICSI were 69.8% and 83.8%, respectively. Blastocyst development ratio after conventional IVF and ICSI were 57.1% and 48.9%, respectively. Finally, the mean number of cryopreserved cleavage embryos or blastocysts, which were categorized as morphologically and developmentally competent embryos, was 3.9 AE 0.3. In two cycles, no competent embryo for freezing was obtained after oocyte retrieval and IVF (Fig. 1) .
Pregnancy outcomes after single vitrified-warmed blastocyst transfer
The outcomes of the 135 single ET cycles in 77 women are shown in Table 3 . The rates of clinical pregnancy and live birth in 26 single cleavage ET cycles were 34.6% (9/26 ET) and 26.9% (7/26 ET), respectively. The outcomes of single vitrified-warmed blastocyst transfer showed that clinical pregnancy and live birth rates were 65.1% (71/109 ET) and 50.5% (55/109 ET), respectively. The clinical miscarriage rates per pregnancy were 22.2% (2/9 pregnancies) in cleavage ET cycles and 22.5% (16/71 pregnancies) in blastocyst transfer cycles. Multiple conceptions and OHSS did not occur in any of the women with HH in the present study. When women with HH produced morphologically and developmentally competent blastocysts, more than half of them successfully delivered babies after single vitrified-warmed blastocyst transfer during HR cycles.
We also analyzed the crude and expected cumulative live birth rates with 95% confidence intervals (CI) after the single vitrified-warmed ET procedures ( Table 4 ). The crude cumulative live birth rate at the first oocyte retrieval was 55.7% (CI: 44.6-66.2), and the rate at the third oocyte retrieval was 73.4% (CI: 62.6-82.0). Finally, the expected cumulative live birth at the third oocyte retrieval was 83.1% (CI: 70.1-91.1). 
Discussion
Women with HH have abnormalities in the HPG axis and ovarian function but have age-dependent dormant follicles in their ovaries. 4, 19 Theoretically, optimal physiological activation of ovarian follicles via gonadotropin administration can induce the development of single follicles and prevent multiple pregnancies and OHSS. Yet, it is difficult to implement a protocol personalized to the ovarian response of patients with HH. In this study, approximately 10 oocytes were retrieved after the injection of hMG and hCG (Table 2 ). An average of 3.9 embryos of morphologically and developmentally competent quality were cryopreserved after IVF/ICSI, meaning that single oocyte retrieval yields nearly four attempts of single vitrified-warmed ET in a subsequent HR cycle ( Table 2 ). The present study showed that the rates of clinical pregnancy and live birth were 59.3% and 45.9%, respectively. The cumulative live birth rate at the first oocyte retrieval was 55.7%, and the live birth rate was expected to be >80% after the third oocyte retrieval (Tables 3 and 4) .
Multiple fresh ET were chosen as the main strategy for women with HH in previous studies.
9,13,14 Ulug et al. reported that the clinical pregnancy and multiple pregnancy rates were 56.6% (30/53 ET cycles) and 46.6% (14/30 pregnancies), respectively, in 58 women with HH after multiple fresh ET (average number of transferred embryos: 3.0 AE 1.3).
14 Recently, a clinical pregnancy rate of 19.4% (14/72 ET cycles) and live birth rate of 15.2% (11/72 ET cycles) with a multiple conception rate of 28.5% (4/14 pregnancies) in 81 women with HH were reported. 13 Ovarian stimulation associated with supraphysiological levels of steroid hormones can disturb optimal uterine receptivity and embryo implantation by perturbation of embryo-endometrial synchrony. [20] [21] [22] [23] [24] [25] [26] [27] It is possible that the endometrial condition was not optimal for implantation in women with HH after ovarian stimulation with exogenous gonadotropins, and ET with multiple fresh embryos demonstrated relatively low OHSS and miscarriage rates but a high multiple pregnancy rate. 13, 14 Most patients with HH have impaired uterine development after long-term amenorrhea. 28 Those patients may have higher risks of multiple pregnancy, including preterm labor and premature infant, compared to those of women with a normal uterus. Single vitrified-warmed ET during the cycles following egg retrieval with HR treatment may optimize synchronization of the interaction between a receptive endometrium and a high-quality embryo with minimization of the adverse effects of ovarian stimulation, leading to improved pregnancy outcomes without risk of multiple conceptions in women with HH. 
Conclusion
In conclusion, the results of the present study demonstrated that IVF followed by single vitrified-warmed ET in adjusted endocrine milieu during the HR cycle is an effective fertility treatment for women with HH and improves the live birth rate and decreases the incidence of complications, including multiple conceptions.
